Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3061475 | 0.87 | SCD (0.52) | SCDSMN1; SMN2PTGDR2MEN1POLB | |
| SCHEMBL3057128 | 0.80 | FYN (0.45) | PTGDR2 | |
| SCHEMBL3067789 | 0.78 | IKBKB (0.48) | MEN1KMT2A | |
| SCHEMBL3062042 | 0.78 | POLB (0.49) | PTGDR2MEN1POLBKMT2A | |
| SCHEMBL3066312 | 0.78 | LMNA (0.45) | SCDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3061575 | 0.75 | KMT2A (0.41) | SMN1; SMN2MEN1POLBKMT2A | |
| SCHEMBL3066290 | 0.75 | EPHX2 (0.47) | PTGDR2MEN1KMT2A | |
| SCHEMBL214943 | 0.75 | SCD (0.51) | SCDMEN1POLBKMT2A | |
| SCHEMBL3069278 | 0.74 | HPGD (0.52) | MEN1POLBKMT2A | |
| SCHEMBL3067615 | 0.71 | PTGDR2 (0.44) | SMN1; SMN2PTGDR2MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267748-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-10-21 | — | — | US | claimed |
| US-20100267748-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267748-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, FADS2 | SCD 1/4885SMN1; SMN2 2207/4885PTGDR2 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.